DDInter576 DDInter1270
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms (acetaldehyde syndrome). It acts by inhibiting aldehyde dehydrogenase.
Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely expressed across and within neuroblastomas (and other neuroectodermal tumors), and is rarely subject to antigen loss. The first anti-GD2-monoclonal IgG antibody to be approved by the FDA for the treatment of neuroblastoma was [dinutuximab] under the brand name Unituxin in 2015. One stark disadvantage of this therapy is the requirement for concurrent use of granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA). Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. This approval requires naxitamab to be co-administered only with GM-CSF, a factor known to enhance the granulocyte-mediated antibody-dependent cytotoxicity of anti-GD2 therapies, making the administration of naxitamab therapy markedly simpler than that of its predecessor.
Disulfiram {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Disulfiram {u} (Compound) downregulates {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Disulfiram {u} (Compound) causes {v} (Side Effect) Tenderness
Tenderness {u} (Side Effect) is caused by {v} (Compound) Ifosfamide
Ifosfamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Disulfiram {u} (Compound) causes {v} (Side Effect) Polyneuropathy
Polyneuropathy {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Naxitamab
Disulfiram {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) is bound by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Disulfiram {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Leflunomide
Leflunomide {u} may lead to a major life threatening interaction when taken with {v} Naxitamab
Disulfiram {u} (Compound) downregulates {v} (Gene) CDC25B
CDC25B {u} (Gene) is upregulated by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Disulfiram {u} (Compound) upregulates {v} (Gene) SLC7A11
SLC7A11 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Disulfiram {u} (Compound) upregulates {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is downregulated by {v} (Compound) Rosuvastatin
Rosuvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naxitamab
Disulfiram {u} (Compound) downregulates {v} (Gene) CCDC86
CCDC86 {u} (Gene) is downregulated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Naxitamab
Disulfiram (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Disulfiram (Compound) downregulates STUB1 (Gene) and STUB1 (Gene) is downregulated by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Disulfiram (Compound) causes Tenderness (Side Effect) and Tenderness (Side Effect) is caused by Ifosfamide (Compound) and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Disulfiram (Compound) causes Polyneuropathy (Side Effect) and Polyneuropathy (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Naxitamab
Disulfiram (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) is bound by Rosuvastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Disulfiram (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound) and Leflunomide may lead to a major life threatening interaction when taken with Naxitamab
Disulfiram (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is upregulated by Rosuvastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Disulfiram (Compound) upregulates SLC7A11 (Gene) and SLC7A11 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Disulfiram (Compound) upregulates NFKBIA (Gene) and NFKBIA (Gene) is downregulated by Rosuvastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Disulfiram (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Naxitamab